Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Dow
UBS
Farmers Insurance
QuintilesIMS
Express Scripts
Julphar
Johnson and Johnson
Argus Health
Mallinckrodt

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,667,061

« Back to Dashboard

Which drugs does patent 6,667,061 protect, and when does it expire?


Patent 6,667,061 protects VIVITROL, BYDUREON, BYDUREON PEN, BYDUREON BCISE, FARXIGA, and RISPERDAL CONSTA, and is included in five NDAs.

Protection for RISPERDAL CONSTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-three patent family members in twenty-six countries.

Summary for Patent: 6,667,061

Title: Preparation of injectable suspensions having improved injectability
Abstract:Injectable compositions having improved injectability. The injectable compositions include microparticles suspended in an aqueous injection vehicle having a viscosity of at least 20 cp at 20.degree. C. The increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures. The injectable compositions can be made by mixing dry microparticles with an aqueous injection vehicle to form a suspension, and then mixing the suspension with a viscosity enhancing agent to increase the viscosity of the fluid phase of the suspension to the desired level for improved injectability.
Inventor(s): Ramstack; J. Michael (Lebanon, OH), Riley; M. Gary I. (Cambridge, MA), Zale; Stephen E. (Hopkinton, MA), Hotz; Joyce M. (Cincinnati, OH), Johnson; Olufunmi L. (Cambridge, MA)
Assignee: Alkermes Controlled Therapeutics, Inc. (Cambridge, MA)
Application Number:10/259,949
Patent Claim Types:
see list of patent claims
Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
AlkermesVIVITROLnaltrexoneFOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897-001Apr 13, 2006RXYesYes► Subscribe► Subscribe► SubscribeY
Astrazeneca AbBYDUREONexenatide syntheticFOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS022200-001Jan 27, 2012RXYesYes► Subscribe► Subscribe► SubscribeY
Astrazeneca AbBYDUREON PENexenatide syntheticFOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS022200-002Feb 28, 2014RXYesYes► Subscribe► Subscribe► SubscribeY
Astrazeneca AbBYDUREON BCISEexenatideSUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS209210-001Oct 20, 2017RXYesYes► Subscribe► Subscribe► SubscribeY
Astrazeneca AbFARXIGAdapagliflozin propanediolTABLET;ORAL202293-001Jan 8, 2014RXYesNo► Subscribe► Subscribe► SubscribeY
Astrazeneca AbFARXIGAdapagliflozin propanediolTABLET;ORAL202293-002Jan 8, 2014RXYesYes► Subscribe► Subscribe► SubscribeY
Janssen PharmsRISPERDAL CONSTArisperidoneINJECTABLE;INTRAMUSCULAR021346-001Oct 29, 2003RXYesYes► Subscribe► Subscribe► SubscribeY
Janssen PharmsRISPERDAL CONSTArisperidoneINJECTABLE;INTRAMUSCULAR021346-002Oct 29, 2003RXYesNo► Subscribe► Subscribe► SubscribeY
Janssen PharmsRISPERDAL CONSTArisperidoneINJECTABLE;INTRAMUSCULAR021346-003Oct 29, 2003RXYesNo► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,667,061

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,495,164 Preparation of injectable suspensions having improved injectability► Subscribe
7,799,345Preparation of injectable suspensions having improved injectability► Subscribe
7,371,406Preparation of injectable suspensions having improved injectability► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,667,061

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia2269577► Subscribe
Slovenia1754469► Subscribe
Slovenia1283699► Subscribe
Russian Federation2002135641► Subscribe
Portugal2269577► Subscribe
Portugal1283699► Subscribe
Poland204298► Subscribe
Poland365195► Subscribe
New Zealand522335► Subscribe
Norway334660► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Daiichi Sankyo
Covington
Baxter
UBS
Express Scripts
US Department of Justice
Deloitte
QuintilesIMS
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot